MedPacto Demonstrates Promising Therapeutic Effects of Combination Clinical Trial for Gastric Cancer at European Society for Medical Oncology

Promising Treatment Effect Demonstrated by Progression-Free Survival (PFS) Extension Compared to Other Combination Therapies

[Asia Economy Reporter Eunmo Koo] MedPacto has unveiled a poster presenting early results from the Phase 1b clinical trial for gastric cancer at the European Society for Medical Oncology Annual Meeting (ESMO Congress 2020).

On the 29th, MedPacto announced that it presented the Phase 1b clinical trial results of the combination therapy of the anticancer new drug under development, ‘Becatacicept,’ and the gastric cancer treatment ‘Paclitaxel’ in patients with metastatic gastric adenocarcinoma.

According to the poster, for the Phase 1b combination therapy, Becatacicept was administered twice daily at doses of 100mg, 200mg, and 300mg for 5 days a week followed by 2 days off, while Paclitaxel was co-administered once weekly at 80mg/m2. The results showed no dose-limiting toxicities (DLT) in any patients, and the median progression-free survival (PFS) was 4.4 months.

A MedPacto official stated, “Notably, the patient groups receiving the effective doses of Becatacicept at 200mg and 300mg twice daily recorded a median PFS of 5.5 months,” adding, “This shows a significant improvement compared to the previously reported PFS of 2.9 months for Paclitaxel monotherapy and 4.4 months for the Paclitaxel-Syramza combination therapy, which is the preferred second-line treatment.”

Becatacicept modulates the tumor microenvironment, helping various cancer therapies attack cancer cells and inhibiting tumor growth and metastasis. When co-administered with Paclitaxel, Becatacicept not only suppresses cancer cell metastasis but also minimizes resistance issues, resulting in a synergistic effect that improves patient survival rates, according to the company.

In fact, the U.S. global pharmaceutical company Eli Lilly demonstrated that the Syramza-Paclitaxel combination therapy significantly improved overall survival (OS) and progression-free survival (PFS) compared to monotherapy, leading to its approval by the U.S. FDA in 2014 as a new standard treatment.

MedPacto appears to have secured meaningful data on efficacy through PFS, a key endpoint for survival extension, while also demonstrating safety with these clinical results.

The company is currently conducting a Phase 2 clinical trial by increasing the recommended Phase 2 dose (RP2D) to 300mg. They expect the median PFS to improve further compared to the Phase 1 trial, which involved low-dose combination therapy.

Meanwhile, MedPacto plans to participate in the upcoming SITC 2020 (Society for Immunotherapy of Cancer Annual Meeting) in the U.S. this November, where it will present two clinical results, including interim data from the Phase 2a trial of the anticancer new drug ‘Becatacicept’ and ‘Imfinzi’ being developed for non-small cell lung cancer patients.

This content was produced with the assistance of AI translation services.